Skip to main content

Venkatesan Jay's Form 4 filing

Elicio Therapeutics, Inc. (ELTX) · filed Dec 29, 2021

Accession no.
0001601485-21-000095
Filed
Dec 29, 2021
Trade date
Dec 27-28, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $730.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Venkatesan JayCIK 0001413350Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 27, 2021Common StockPPurchaseAcquired+66,907$2.55F1+$170,612.851,428,920Direct
Dec 28, 2021Common StockPPurchaseAcquired+210,337$2.66F2+$559,496.421,639,257Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.55 inclusive.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.75 inclusive.

Referenced by the price of 1 transaction in Table I.

Remarks

President and Chief Executive Officer and Director

Read the full filing on SEC EDGAR (opens in a new tab)